GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio, Inc. announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,007,970 titled, “Prevention and Treatment of Inflammatory Conditions.” The patent will cover claims including compositions and methods for modulating type 2 and/or type 1 (iNKT) cells in the prevention and treatment of inflammatory conditions of the liver.